Bedford, Mass., Sept 29 (Bernama-GLOBE NEWSWIRE) —Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing inflammation, protecting against oxidative stress in cells, and providing relief from depression, fatigue, and stress. Salidroside has also been used to alleviate high altitude sickness.
Unlike other salidroside products currently on the market, Conagen’s salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant — the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions which are available from their pipeline partner, Sweegen.